Cenova Capital is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU and was one of the few funds selected and invested by the Chinese government to foster the government’s goal to transform the healthcare system in China from a state-owned system to a private and market-oriented system.
Through the years, Cenova has built a reputation among its current and potential portfolio companies, industry leaders, multinational companies and its peers, as a leading fund for life science investments in China.
Currently, Cenova has four funds under management with a combined AUM of over USD600 million.
- Fund I: RMB (2010)
- Fund II: RMB (2012)
- Fund III: RMB (2015)
- Fund IV: RMB and USD (2017)
It has invested in more than 40 companies with a proven track record across 3 funds. Its investors include large domestic and international institutional investors including sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies specializing in pharmaceuticals, medical devices and diagnostics.